Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD
Metabolism: Clinical and Experimental, Volume 128, Article 154958, Year 2022
Notification
URL copied to clipboard!
Description
Background: With metabolic dysfunction-associated fatty liver disease (MAFLD) incidence and prevalence increasing, it is necessary to identify patients with advanced fibrosis (F3-F4 stages). We evaluated the performance of new biomarkers and algorithms for diagnosing advanced fibrosis in an Asian population. Methods: Data from two Asian cohorts (including 851 biopsy-proven MAFLD [578 from Wenzhou, 273 from Hong Kong]) were studied. The association between N-terminal propeptide of type 3 collagen (PRO-C3) and the histologic stage of liver fibrosis was analyzed by multivariable linear regression. The area under the receiver operating characteristic curve (AUROC) was used to test the diagnostic performance of serum PRO-C3 and the ADAPT score for advanced fibrosis and compared them to other established non-invasive tests. Results: Serum PRO-C3 levels increased progressively across liver fibrosis stages and correlated with advanced fibrosis (P < 0.001). The ADAPT score had an AUROC of 0.865 (95% confidence interval 0.829–0.901) for advanced fibrosis; the accuracy, sensitivity and negative predictive values were 81.4%, 82.2% and 96.1%, respectively. This result was better compared to that of PRO-C3 alone or other non-invasive fibrosis biomarkers (aspartate aminotransferase-to-platelet ratio index, Fibrosis-4, BARD, and NAFLD fibrosis score). In subgroup analyses (including sex, age, diabetes, NAFLD activity score, body mass index or serum alanine aminotransferase levels), the ADAPT score had good diagnostic performance. Conclusion: PRO-C3 and the ADAPT score reliably exclude advanced fibrosis in MAFLD patients and reduce the need for liver biopsy. © 2021 Elsevier Inc.
Authors & Co-Authors
Eslam, Mohammed
Australia, Parramatta
The Westmead Institute for Medical Research
Wong, Grace Lai Hung
Hong Kong, Hong Kong
Chinese University of Hong Kong
Leeming, Diana Julie
Denmark, Herlev
Nordic Bioscience as
Karsdal, Morten Asser
Denmark, Herlev
Nordic Bioscience as
Byrne, Christopher D.
United Kingdom, Southampton
University Hospital Southampton Nhs Foundation Trust
Targher, Giovanni
Italy, Verona
Azienda Ospedaliera Universitaria Integrata Verona
George, Jacob A.
Australia, Parramatta
The Westmead Institute for Medical Research
Wong, Vincent Wai Sun
Hong Kong, Hong Kong
Chinese University of Hong Kong
Zheng, Minghua
China, Wenzhou
The First Affiliated Hospital of Wenzhou Medical University
China, Wenzhou
Wenzhou Medical University
China, Wenzhou
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province
Statistics
Citations: 14
Authors: 9
Affiliations: 9
Identifiers
Doi:
10.1016/j.metabol.2021.154958
ISSN:
00260495
Research Areas
Noncommunicable Diseases
Study Design
Cross Sectional Study
Cohort Study